September 19, 2024 | 3:50 PM
READING TIME: 2 minutes
“We welcome all therapeutic innovations that can normalize the course of psoriasis, also because the average time to access specific treatments for us patients is 12 years. An eternity, if we consider that psoriasis has a strong impact on daily life, as the symptoms are very visible and cause a sense of shame and frustration. We are talking about a chronic and relapsing disease, but it is not yet included in the National Chronicity Plan. It is a battle that we have been fighting for 4 years to give ‘dignity to the disease'”. Valeria Corazza, president of Apiafco-Associazione psoriasici italiani amici Fondazione Corazza, said this while speaking at the press conference in Rome on the approval of reimbursement for the drug deucravacitinib.
“Today living with psoriasis is certainly not like when I was diagnosed when I was 10 years old – she explains to Adnkronos Salute – Today we have many therapeutic proposals available that can treat those who have two spots but, above all, those 250 thousand patients who suffer from severe psoriasis and who for this reason can have 90% of their body covered in plaques or localized on the face and hands, our calling card. So being able to have more therapeutic options is no small thing”. However, for the patient representative, “there is still a lack of information. As an association we work on this aspect – Corazza underlines – because many people continue not to seek treatment, they are afraid of the side effects of therapies or abandon them, or they do not know which center and which specialist to turn to”. “Believe me, there are those who do not know where to go, there are those who do not know the wonderful things that are done for this pathology that when it is in severe form is a devastating disease”, she concludes.
#Corazza #Apiafco #Psoriasis #patients #wait #years #specific #therapies